Download PDF
Hamostaseologie 2024; 44(05): 393-398
DOI: 10.1055/a-2159-8722
Case Report

Management of Recurrent Venous Thromboembolism in Severe Immune Thrombocytopenia: A Case Report and a Review of the Literature

Mathias Haargaard Nielsen
1   Haematology Unit, Department of Internal Medicine, University Hospital of Southern Denmark, Esbjerg, Denmark
,
Mustafa Vakur Bor
2   Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Esbjerg, Denmark
3   Thrombosis and Anticoagulation Clinic, Department of Clinical Biochemistry, University Hospital of Southern Denmark, Esbjerg, Denmark
› Author Affiliations Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
› Further Information
Also available at
   Permissions and Reprints

Abstract

We report a case of a 58-year-old man with recurrent unprovoked deep vein thrombosis (DVT) and severe immune thrombocytopenia (ITP) with a platelet count of 19 × 109/L. We further review studies reporting venous thromboembolism (VTE) in patients with severe ITP (≤ 35 × 109/L) and identified 14 patients highlighting VTE risk factors and management of these patients. The present case had several risk factors for VTE (previous DVT, obesity, heterozygosity for factor V Leiden mutation, and previous splenectomy). The patient was initially treated with low-molecular-weight heparin followed by long-term apixaban treatment. The literature review together with our case demonstrates that VTE in severe ITP (≤ 35 × 109/L) can occur in patients with VTE risk factors and antithrombotic management of these patients can be achieved without bleeding depending on severity of thrombocytopenia either by full or reduced dose of anticoagulation together with ITP therapy.

Keywords

immune thrombocytopenia - venous thromboembolism - thrombotic disorder

Statement of Ethics

An ethical review is not required for this type of article. The patient is aware that his clinical details are used in this article. Written consent was given by the patient.


Authors' Contributions

M.H.N. performed the literature review, interpreted the data, and wrote the first draft of the manuscript and approved the final manuscript.


M.V.B. planned the study, supervised for the recruitment of the subject, performed the literature review, interpreted the data, and supervised the writing of the manuscript, and approved the final manuscript.


Data Availability

The data supporting the findings of this study are available on request due to privacy/ethical restrictions.




Publication History

Received: 17 April 2023

Accepted: 23 August 2023

Article published online:
31 October 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Le Guenno G, Guieze R, Audia S. et al. Characteristics, risk factors and management of venous thromboembolism in immune thrombocytopenia: a retrospective multicentre study. Intern Med J 2019; 49 (09) 1154-1162
    CrossrefPubMedSearch in Google Scholar
  • 2 Nørgaard M, Cetin K, Maegbaek ML. et al. Risk of arterial thrombotic and venous thromboembolic events in patients with primary chronic immune thrombocytopenia: a Scandinavian population-based cohort study. Br J Haematol 2016; 174 (04) 639-642
    CrossrefPubMedSearch in Google Scholar
  • 3 Rodeghiero F. Is ITP a thrombophilic disorder?. Am J Hematol 2016; 91 (01) 39-45
    CrossrefPubMedSearch in Google Scholar
  • 4 Arnold DM. Bleeding complications in immune thrombocytopenia. Hematology (Am Soc Hematol Educ Program) 2015; 2015: 237-242
    CrossrefPubMedSearch in Google Scholar
  • 5 Klok FA, Hösel V, Clemens A. et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Respir J 2016; 48 (05) 1369-1376
    CrossrefPubMedSearch in Google Scholar
  • 6 Lee YJ, Shin JU, Lee J. et al. A case of deep vein thrombosis and pulmonary thromboembolism after intravenous immunoglobulin therapy. J Korean Med Sci 2007; 22 (04) 758-761
    CrossrefPubMedSearch in Google Scholar
  • 7 Ho P, Khan S, Crompton D, Hayes L. Extensive cerebral venous sinus thrombosis after romiplostim treatment for immune thrombocytopenia (ITP) despite severe thrombocytopenia. Intern Med J 2015; 45 (06) 682-683
    CrossrefPubMedSearch in Google Scholar
  • 8 İlhan G, Toprak SK, Andıç N, Karakuş S. Idiopathic thrombocytopenic purpura with venous thrombosis: a case report. Turk J Haematol 2010; 27 (03) 209-210
    CrossrefPubMedSearch in Google Scholar
  • 9 Takeuchi T, Matsuura Y, Yamamura Y. et al. A likely unavoidable clinical scenario during treatment for venous thromboembolism complicated with severe immune thrombocytopenia: a case report. Clin Case Rep 2021; 9 (09) e04805
    CrossrefPubMedSearch in Google Scholar
  • 10 Kang J, Lee JS, Lee JH, Lee KM. Recurrent pulmonary embolism during dabigatran treatment in a patient with immune thrombocytopenic purpura. Thromb Res 2016; 148: 23-24
    CrossrefPubMedSearch in Google Scholar
  • 11 Tan Y, Yan M, Cheng Z, Pan X. Pulmonary thromboembolism in immune thrombocytopenia: a report of five cases and a review of the literature. Int J Gen Med 2021; 14: 4479-4483
    CrossrefPubMedSearch in Google Scholar
  • 12 Ennis G, Domingues N, Silva Marques J, Ribeiro P, Andrade C. Cerebral venous thrombosis and its clinical diversity. Cureus 2021; 13 (04) e14750
    PubMedSearch in Google Scholar
  • 13 Indolfi G, Bartolini E, Resti M. Differential diagnosis between immune (idiopathic) thrombocytopenic purpura and portal vein thrombosis in children. Eur J Haematol 2009; 83 (06) 607-608
    CrossrefPubMedSearch in Google Scholar
  • 14 Han X, Li C, Zhang S. et al. Why thromboembolism occurs in some patients with thrombocytopenia and treatment strategies. Thromb Res 2020; 196: 500-509
    CrossrefPubMedSearch in Google Scholar
  • 15 Rand ML, Dean JA. Platelet function in autoimmune (idiopathic) thrombocytopenic purpura. Acta Paediatr Suppl 1998; 424: 57-60
    CrossrefPubMedSearch in Google Scholar
  • 16 Luo S, Hu D, Wang M, Zipfel PF, Hu Y. Complement in hemolysis- and thrombosis- related diseases. Front Immunol 2020; 11: 1212
    CrossrefPubMedSearch in Google Scholar
  • 17 Kim KJ, Baek IW, Yoon CH, Kim WU, Cho CS. Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies. Br J Haematol 2013; 161 (05) 706-714
    CrossrefPubMedSearch in Google Scholar
  • 18 Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood 2013; 121 (23) 4782-4790
    CrossrefPubMedSearch in Google Scholar
  • 19 Swan D, Newland A, Rodeghiero F, Thachil J. Thrombosis in immune thrombocytopenia - current status and future perspectives. Br J Haematol 2021; 194 (05) 822-834
    CrossrefPubMedSearch in Google Scholar
  • 20 Shaheen K, Alraies MC, Alraiyes AH, Christie R. Factor V Leiden: how great is the risk of venous thromboembolism?. Cleve Clin J Med 2012; 79 (04) 265-272
    CrossrefPubMedSearch in Google Scholar
  • 21 Hui C, Brodsky RA, Haines C. Bilateral pulmonary embolism with right heart strain in a patient with immune thrombocytopenia - a case report and review of the literature. Pediatr Emerg Care 2020; 36 (04) e227-e228
    CrossrefPubMedSearch in Google Scholar
  • 22 Adelborg K, Kristensen NR, Nørgaard M. et al. Cardiovascular and bleeding outcomes in a population-based cohort of patients with chronic immune thrombocytopenia. J Thromb Haemost 2019; 17 (06) 912-924
    CrossrefPubMedSearch in Google Scholar
  • 23 Balitsky AK, Kelton JG, Arnold DM. Managing antithrombotic therapy in immune thrombocytopenia: development of the TH2 risk assessment score. Blood 2018; 132 (25) 2684-2686
    CrossrefPubMedSearch in Google Scholar
  • 24 Bolton-Maggs PHB, George JN. Immune thrombocytopenia treatment. N Engl J Med 2021; 385 (10) 948-950
    CrossrefPubMedSearch in Google Scholar
  • 25 Cuker A, Liebman HA. Corticosteroid overuse in adults with immune thrombocytopenia: cause for concern. Res Pract Thromb Haemost 2021; 5 (06) e12592
    CrossrefPubMedSearch in Google Scholar
  • 26 Brotman DJ, Girod JP, Posch A. et al. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res 2006; 118 (02) 247-252
    CrossrefPubMedSearch in Google Scholar
  • 27 Ramírez E, Romero-Garrido JA, López-Granados E. et al. Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: results from a retrospective cohort study. Thromb Res 2014; 133 (06) 1045-1051
    CrossrefPubMedSearch in Google Scholar
  • 28 Provan D, Arnold DM, Bussel JB. et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 2019; 3 (22) 3780-3817
    CrossrefPubMedSearch in Google Scholar
  • 29 Refaai MA, Phipps RP, Spinelli SL, Blumberg N. Platelet transfusions: impact on hemostasis, thrombosis, inflammation and clinical outcomes. Thromb Res 2011; 127 (04) 287-291
    CrossrefPubMedSearch in Google Scholar
  • 30 Ghanima W, Lee SY, Barsam S, Miller A, Sandset PM, Bussel JB. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists. Br J Haematol 2012; 158 (06) 811-814
    CrossrefPubMedSearch in Google Scholar